Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-6 (of 6 Records) |
Query Trace: Feld J[original query] |
---|
Polyvalent immunization elicits a synergistic broadly neutralizing immune response to hypervariable region 1 variants of hepatitis C virus
Mosa AI , Campo DS , Khudyakov Y , AbouHaidar MG , Gehring AJ , Zahoor A , Ball JK , Urbanowicz RA , Feld JJ . Proc Natl Acad Sci U S A 2023 120 (24) e2220294120 A hepatitis C virus (HCV) vaccine is urgently needed. Vaccine development has been hindered by HCV's genetic diversity, particularly within the immunodominant hypervariable region 1 (HVR1). Here, we developed a strategy to elicit broadly neutralizing antibodies to HVR1, which had previously been considered infeasible. We first applied a unique information theory-based measure of genetic distance to evaluate phenotypic relatedness between HVR1 variants. These distances were used to model the structure of HVR1's sequence space, which was found to have five major clusters. Variants from each cluster were used to immunize mice individually, and as a pentavalent mixture. Sera obtained following immunization neutralized every variant in a diverse HCVpp panel (n = 10), including those resistant to monovalent immunization, and at higher mean titers (1/ID(50) = 435) than a glycoprotein E2 (1/ID(50) = 205) vaccine. This synergistic immune response offers a unique approach to overcoming antigenic variability and may be applicable to other highly mutable viruses. |
Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Ghany MG , Marks KM , Morgan TR , Wyles DL , Aronsohn AI , Bhattacharya D , Broder T , Falade-Nwulia OO , Feld JJ , Gordon SC , Heller T , Jhaveri RR , Jonas MM , Kiser JJ , Linas BP , Lo Re V , Peters MG , Reddy KR , Reynolds A , Scott JD , Searson G , Spradling P , Terrault NA , Trooskin SB , Verna EC , Wong JB , Woolley AE , Workowski KA . Hepatology 2019 71 (2) 686-721 The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C guidance project (hereafter HCV guidance) in 2013. The AASLD-IDSA HCV guidance website (www.HCVGuidelines.org) disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of hepatitis C virus (HCV) infection. Utilizing a web-based system enables timely and nimble distribution of the HCV guidance, which is periodically updated in near real time as necessitated by emerging research data, recommendations from public health agencies, the availability of new therapeutic agents, or other significant developments affecting the rapidly evolving hepatitis C arena. |
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals
Popping S , Bade D , Boucher C , van der Valk M , El-Sayed M , Sigurour O , Sypsa V , Morgan T , Gamkrelidze A , Mukabatsinda C , Deuffic-Burban S , Ninburg M , Feld J , Hellard M , Ward J . J Virus Erad 2019 5 (1) 60-66 Hepatitis B virus (HBV) and hepatitis C virus (HCV) affect more than 320 million people worldwide, which is more than HIV, tuberculosis (TB) and malaria combined. Elimination of HBV and HCV will, therefore, produce substantial public health and economic benefits and, most importantly, the prevention of 1.2 million deaths per year. In 2016, member states of the World Health Assembly unanimously adopted a resolution declaring that viral hepatitis should be eliminated by 2030. Currently, few countries have elimination programmes in place and even though the tools to achieve elimination are available, the right resources, commitments and allocations are lacking. During the fifth International Viral Hepatitis Elimination Meeting (IVHEM), 7-8 December 2018, Amsterdam, the Netherlands, an expert panel of clinicians, virologists and public health specialists discussed the current status of viral hepatitis elimination programmes across multiple countries, challenges in achieving elimination and the core indicators for monitoring progress, approaches that have failed and successful elimination plans. |
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Cooke GS , Andrieux-Meyer I , Applegate TL , Atun R , Burry JR , Cheinquer H , Dusheiko G , Feld JJ , Gore C , Griswold MG , Hamid S , Hellard ME , Hou J , Howell J , Jia J , Kravchenko N , Lazarus JV , Lemoine M , Lesi OA , Maistat L , McMahon BJ , Razavi H , Roberts TR , Simmons B , Sonderup MW , Spearman CW , Taylor BE , Thomas DL , Waked I , Ward JW , Wiktor SZ . Lancet Gastroenterol Hepatol 2019 4 (2) 135-184 Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals. |
Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework
Popping S , El-Sayed M , Feld J , Hatzakis A , Hellard M , Lesi O , Ninburg M , Ward J , Boucher C . J Virus Erad 2018 4 (3) 193-195 The current global burden of hepatitis C (HCV) is estimated at 71 million people. The World Health Organization (WHO) has stated that HCV could be eliminated as a public health threat by 2030. A key recommendation to reach this elimination goal is to reduce new infections by 90% and liver-related mortality by 65%. Countries are encouraged by the WHO to develop their own national elimination programmes in order to reach these goals. However, various gaps and challenges, such as the lack of high-quality epidemiological data, stigmatisation, and optimisation of the cascade of care, have arisen in the WHO strategic framework. The International Viral Hepatitis Elimination Meeting (IVHEM) has therefore established an expert panel made of clinicians, virologists, and public health specialists to discuss and address these challenges. This review highlights the outcome and proposed solutions to attempt at facilitating HCV elimination. |
Evaluation for West Nile Virus (WNV) RNA in urine of patients within 5 months of WNV infection.
Baty SA , Gibney KB , Staples JE , Patterson AB , Levy C , Lehman J , Wadleigh T , Feld J , Lanciotti R , Nugent CT , Fischer M . J Infect Dis 2012 205 (9) 1476-7 Gibney et al recently reported finding no West Nile virus (WNV) RNA in urine samples collected from 40 patients at 6.5–6.7 years after acute WNV disease [1]. These findings were in contrast to Murray et al, who detected WNV RNA in urine samples collected from 5 of 25 patients (20%) at 1.6–6.7 years after their initial infections [2]. We present results from a prospective evaluation of WNV RNA in urine specimens collected from 63 persons within 5 months after their acute WNV infection. | During the 2010 WNV outbreak in Maricopa County, Arizona, we identified persons with laboratory evidence of acute WNV infection, including detection of WNV immunoglobulin M antibodies in serum or cerebrospinal fluid samples from patients with a clinically compatible illness or WNV RNA in serum samples from asymptomatic blood donors. Information on demographic characteristics, medical history, current medications, and clinical illness was obtained by medical record review and interview with patients or their surrogate. A urine sample was collected during a site visit. The study was approved by the Centers for Disease Control and Prevention (CDC) and Arizona Department of Health Services (ADHS) human subjects review boards, and participants provided informed consent before enrollment. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure